Compare HMN & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HMN | PGEN |
|---|---|---|
| Founded | 1945 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1991 | N/A |
| Metric | HMN | PGEN |
|---|---|---|
| Price | $42.53 | $4.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $46.75 | $7.67 |
| AVG Volume (30 Days) | 233.6K | ★ 5.2M |
| Earning Date | 02-03-2026 | 11-13-2025 |
| Dividend Yield | ★ 3.30% | N/A |
| EPS Growth | ★ 56.80 | N/A |
| EPS | ★ 3.95 | N/A |
| Revenue | ★ $1,675,600,000.00 | $6,309,000.00 |
| Revenue This Year | $7.70 | $342.78 |
| Revenue Next Year | $6.46 | $478.46 |
| P/E Ratio | $10.75 | ★ N/A |
| Revenue Growth | 5.44 | ★ 59.20 |
| 52 Week Low | $37.21 | $1.08 |
| 52 Week High | $48.33 | $5.23 |
| Indicator | HMN | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 29.16 | 54.16 |
| Support Level | $44.18 | $4.03 |
| Resistance Level | $46.19 | $4.48 |
| Average True Range (ATR) | 1.06 | 0.34 |
| MACD | -0.38 | -0.02 |
| Stochastic Oscillator | 6.75 | 48.53 |
Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are 403(b) tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.